A Phase 3 interventional study of Bimekizumab and Placebo in Hidradenitis Suppurativa, sponsored by UCB Biopharma SRL. Completed at 91 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Aleshin MA, Tran T, Pansar I, Shang A, Friesen D, Kimball AB. Residual Burden in Adalimumab-Treated Patients with Hidradenitis Suppurativa: An Observational Co…PubMed 42525209 ↗; 1 more
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 161 studies in Hidradenitis Suppurativa with a site in United States — 38 open to participants now, 55 under way, 12 of them phase 3. Hidradenitis Suppurativa · United States.
Among the 161 studies in Hidradenitis Suppurativa with a site in United States, this one is the 17th largest by enrollment of the 139 interventional ones that give a count, is one of 16 that started in 2020, is one of 24 in phase 3, and was the 56th registered.
285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.
Browse Hidradenitis Suppurativa studies →38 of the 161 studies in Hidradenitis Suppurativa with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States
Ages 18–65
Corvus Pharmaceuticals, Inc. · Sites in United States
Ages 18+
Harrison Dermatology · Sites in United States
Ages 12+
Beth Israel Deaconess Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
161 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 65 · Phase 3 27 · Phase 4 5
First in 2005; this study’s year is marked. 16 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 509 is above the median of 45 across 200 interventional studies indexed under Hidradenitis Suppurativa.
Median enrollment 45 across the 139 interventional studies, 300 across the 22 observational. Of the 95 that completed or were terminated, 52 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
87 of 161 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Biopharma SRL, one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
UCB S.A. has 6 studies filed under Hidradenitis Suppurativa — fewer than ten, so there is no comparison to draw.
21 of the studies in Hidradenitis Suppurativa with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06468228Phase 3AbbVieA Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12 |
| NCT06921850Phase 3UCB Biopharma SRLA Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa | 2026-12-21 |
| NCT06212999Phase 3Incyte CorporationA Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12-26 |
| NCT06799000Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) | 2027-05-17 |
| NCT06840392Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa | 2027-06-03 |
Add all 21 to your calendar (.ics) → With an account.
Among the 161 studies in Hidradenitis Suppurativa with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A female study participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects participating in the study will receive assigned bimekizumab dosing regimen 1 during the Treatment Period.
Drug: Bimekizumab
Subjects participating in the study will receive assigned bimekizumab dosing regimen 2 during the Treatment Period.
Drug: Bimekizumab
Subjects participating in the study will receive assigned bimekizumab dosing regimen 3 during the Treatment Period.
Drug: Bimekizumab
Subjects randomized to this arm will receive placebo during the Initial Treatment Period and bimekizumab during the Maintenance Treatment Period.
Drug: Bimekizumab · Other: Placebo
Subjects will receive bimekizumab at pre-specified time-points.
Also known as: UCB4940
Subjects will receive placebo at pre-specified time-points during the Initial Treatment Period.
Also known as: PBO
Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16
HiSCR50 was defined as at least a 50 percent (%) reduction from Baseline in the total abscess and inflammatory nodule (AN) count, with no increase from Baseline in abscess or draining tunnel count. Intermittent missing data are imputed using multiple imputation with Markov Chain Monte Carlo (MCMC) method followed by monotone regression for monotone missing data. Lesion counts were imputed and then dichotomized to obtain the response status. Participants who experienced an intercurrent event were treated as nonresponders following the intercurrent event. An intercurrent event was defined as receipt of systemic antibiotic rescue medication or discontinuation of study treatment due to an adverse event (AE) or lack of efficacy. Percentages of participants shown do not account for model effects using the logistic regression model.
Time frame: Week 16
Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16
HiSCR75 was defined as at least a 75% reduction from Baseline in the total AN count, with no increase from Baseline in abscess or draining tunnel count. Intermittent missing data were imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Lesion counts were imputed and then dichotomized to obtain the response status. Participants who experienced an intercurrent event were treated as nonresponders following the intercurrent event. An intercurrent event was defined as receipt of systemic antibiotic rescue medication or discontinuation of study treatment due to an AE or lack of efficacy. Percentages of participants shown do not account for model effects using the logistic regression model.
Time frame: Week 16
Percentage of Participants With Flare by Week 16
Flare was defined as a greater than or equal to (\>=) 25% increase in AN count with an absolute increase in AN count of \>= 2 relative to Baseline. Intermittent missing data were imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Lesion counts were imputed and then dichotomized to obtain the response status. Participants who experienced an intercurrent event prior to experiencing a flare were treated as having experienced a flare at all flare assessments on and after the intercurrent event date. An intercurrent event was defined as receipt of systemic antibiotic rescue medication or discontinuation of study treatment due to an AE or lack of efficacy. Percentages of participants shown do not account for model effects using the logistic regression model.
Time frame: From Baseline to Week 16
Absolute Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16
The DLQI is a patient-reported questionnaire designed for use in adult participants with skin diseases and Hidradenitis Suppurativa (HS). The DLQI is a skin disease-specific questionnaire aimed at the evaluation of how symptoms and treatment affect patients' health related quality of life (HRQoL), with a recall period of 7 days. This instrument asks participants 10 questions about symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The scoring of each answer for the DLQI is on a scale range of 0 (not at all) to 3 (very much). The DLQI total score was calculated by adding the score of each question. The maximum score is 30, and the minimum score is 0. The higher the score, the more quality of life is impaired. Participants who experienced an intercurrent event were treated as missing following the intercurrent event and imputed using the multiple imputation method for missing data.
Time frame: Baseline, Week 16
Absolute Change From Baseline in Worst Skin Pain Score at Week 16
Absolute change from Baseline in worst Skin Pain score at Week 16 was assessed using the worst skin pain item in the Hidradenitis Suppurativa Symptom Daily Diary (HSSDD). Worst skin pain during the past 24 hours was assessed daily using an 11-point numeric rating scale (NRS) which ranges from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The worst skin pain score was derived from the weekly average of daily scores, defined as the sum of the scored item over the course of the study week divided by the number of days in which the item was completed, relative to each respective visit date. Intermittent missing data are imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Participants who experienced an intercurrent event were treated as missing following the intercurrent event and imputed using the multiple imputation method for missing data. Mean values shown do not account for model effects using the ANCOVA model.
Time frame: Baseline, Week 16
Percentage of Participants Achieving Skin Pain Response at Week 16
Skin pain response at Week 16, as assessed by "worst skin pain" item in HSSDD, was defined as an improvement in weekly worst skin pain score of at least 3 points versus Baseline. Worst skin pain during the past 24 hours was assessed daily using an 11-point numeric rating scale (NRS) which ranges from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). Worst skin pain score was derived from weekly average of daily scores (sum of scored item over study week/number of days in which item completed, relative to each respective visit). Intermittent missing data were imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Weekly pain scores were imputed and then dichotomized to obtain response status. Participants who experienced an intercurrent event were treated as non-responders following the intercurrent event. Percentages of participants shown do not account for model effects using logistic regression model.
Time frame: Week 16
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. Treatment-emergent AEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week Safety Follow-Up \[SFU\] period).
Time frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 71)
Percentage of Participants With Serious Treatment-emergent Adverse Events During the Study
A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: Results in death; Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization; Results in persistent disability/incapacity; Is a congenital anomaly/birth defect; Important medical events. Treatment-emergent AEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period).
Time frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 71)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From the Study
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. Treatment-emergent AEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period). TEAEs leading to discontinuation of the study are reported.
Time frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 71)
The study started to enroll participants in March 2020 and concluded in September 2022.
| Milestone | Placebo | BKZ Dosing Regimen 1 | BKZ Dosing Regimen 2 | Placebo/BKZ Dosing Regimen 2 | BKZ Dosing Regimen 1/BKZ Dosing Regimen 1 | BKZ Dosing Regimen 2/BKZ Dosing Regimen 1 | BKZ Dosing Regimen 2/BKZ Dosing Regimen 2 |
|---|---|---|---|---|---|---|---|
| Started | 74 | 144 | 291 | 0 | 0 | 0 | 0 |
| Completed | 69 | 133 | 262 | 0 | 0 | 0 | 0 |
| Not completed | 5 | 11 | 29 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 1 | 9 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Consent withdrawn by subject, not due to ae | 2 | 8 | 12 | 0 | 0 | 0 | 0 |
| Withdrew: Subject moved long distance from clinic (abroad) | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawn by investigator's decision | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Randomized, not treated | 0 | 2 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Placebo | BKZ Dosing Regimen 1 | BKZ Dosing Regimen 2 | Placebo/BKZ Dosing Regimen 2 | BKZ Dosing Regimen 1/BKZ Dosing Regimen 1 | BKZ Dosing Regimen 2/BKZ Dosing Regimen 1 | BKZ Dosing Regimen 2/BKZ Dosing Regimen 2 |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 69 | 133 | 130 | 131 |
| Completed | 0 | 0 | 0 | 61 | 109 | 107 | 110 |
| Not completed | 0 | 0 | 0 | 8 | 24 | 23 | 21 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 7 | 6 | 4 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 4 | 2 | 2 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 2 | 3 | 1 | 2 |
| Withdrew: Consent withdrawn by subject, not due to ae | 0 | 0 | 0 | 6 | 9 | 10 | 11 |
| Withdrew: Change in address-patient not wanting to continue | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Visits too time-consuming, only sfu will be done | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Subject relocated | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
HiSCR50 was defined as at least a 50 percent (%) reduction from Baseline in the total abscess and inflammatory nodule (AN) count, with no increase from Baseline in abscess or draining tunnel count. Intermittent missing data are imputed using multiple imputation with Markov Chain Monte Carlo (MCMC) method followed by monotone regression for monotone missing data. Lesion counts were imputed and then dichotomized to obtain the response status. Participants who experienced an intercurrent event were treated as nonresponders following the intercurrent event. An intercurrent event was defined as receipt of systemic antibiotic rescue medication or discontinuation of study treatment due to an adverse event (AE) or lack of efficacy. Percentages of participants shown do not account for model effects using the logistic regression model.
| percentage of participants | Placebo | BKZ Dosing Regimen 1 | BKZ Dosing Regimen 2 |
|---|---|---|---|
| Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16 | 32.2 (21.4 to 42.9) | 53.8 (45.4 to 62.1) | 52.0 (46.1 to 57.8) |
HiSCR75 was defined as at least a 75% reduction from Baseline in the total AN count, with no increase from Baseline in abscess or draining tunnel count. Intermittent missing data were imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Lesion counts were imputed and then dichotomized to obtain the response status. Participants who experienced an intercurrent event were treated as nonresponders following the intercurrent event. An intercurrent event was defined as receipt of systemic antibiotic rescue medication or discontinuation of study treatment due to an AE or lack of efficacy. Percentages of participants shown do not account for model effects using the logistic regression model.
| percentage of participants | Placebo | BKZ Dosing Regimen 1 | BKZ Dosing Regimen 2 |
|---|---|---|---|
| Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16 | 15.6 (7.2 to 24.0) | 33.7 (25.7 to 41.7) | 35.7 (30.1 to 41.3) |
Flare was defined as a greater than or equal to (\>=) 25% increase in AN count with an absolute increase in AN count of \>= 2 relative to Baseline. Intermittent missing data were imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Lesion counts were imputed and then dichotomized to obtain the response status. Participants who experienced an intercurrent event prior to experiencing a flare were treated as having experienced a flare at all flare assessments on and after the intercurrent event date. An intercurrent event was defined as receipt of systemic antibiotic rescue medication or discontinuation of study treatment due to an AE or lack of efficacy. Percentages of participants shown do not account for model effects using the logistic regression model.
| percentage of participants | Placebo | BKZ Dosing Regimen 1 | BKZ Dosing Regimen 2 |
|---|---|---|---|
| Percentage of Participants With Flare by Week 16 | 28.0 (17.6 to 38.4) | 23.6 (16.5 to 30.7) | 28.8 (23.5 to 34.1) |
The DLQI is a patient-reported questionnaire designed for use in adult participants with skin diseases and Hidradenitis Suppurativa (HS). The DLQI is a skin disease-specific questionnaire aimed at the evaluation of how symptoms and treatment affect patients' health related quality of life (HRQoL), with a recall period of 7 days. This instrument asks participants 10 questions about symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The scoring of each answer for the DLQI is on a scale range of 0 (not at all) to 3 (very much). The DLQI total score was calculated by adding the score of each question. The maximum score is 30, and the minimum score is 0. The higher the score, the more quality of life is impaired. Participants who experienced an intercurrent event were treated as missing following the intercurrent event and imputed using the multiple imputation method for missing data.
| score on a scale | Placebo | BKZ Dosing Regimen 1 | BKZ Dosing Regimen 2 |
|---|---|---|---|
| Absolute Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16 | -3.2 ± 0.6 | -4.7 ± 0.5 | -4.6 ± 0.3 |
Absolute change from Baseline in worst Skin Pain score at Week 16 was assessed using the worst skin pain item in the Hidradenitis Suppurativa Symptom Daily Diary (HSSDD). Worst skin pain during the past 24 hours was assessed daily using an 11-point numeric rating scale (NRS) which ranges from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The worst skin pain score was derived from the weekly average of daily scores, defined as the sum of the scored item over the course of the study week divided by the number of days in which the item was completed, relative to each respective visit date. Intermittent missing data are imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Participants who experienced an intercurrent event were treated as missing following the intercurrent event and imputed using the multiple imputation method for missing data. Mean values shown do not account for model effects using the ANCOVA model.
| score on a scale | Placebo | BKZ Dosing Regimen 1 | BKZ Dosing Regimen 2 |
|---|---|---|---|
| Absolute Change From Baseline in Worst Skin Pain Score at Week 16 | -0.36 ± 0.30 | -1.44 ± 0.24 | -1.83 ± 0.17 |
Skin pain response at Week 16, as assessed by "worst skin pain" item in HSSDD, was defined as an improvement in weekly worst skin pain score of at least 3 points versus Baseline. Worst skin pain during the past 24 hours was assessed daily using an 11-point numeric rating scale (NRS) which ranges from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). Worst skin pain score was derived from weekly average of daily scores (sum of scored item over study week/number of days in which item completed, relative to each respective visit). Intermittent missing data were imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Weekly pain scores were imputed and then dichotomized to obtain response status. Participants who experienced an intercurrent event were treated as non-responders following the intercurrent event. Percentages of participants shown do not account for model effects using logistic regression model.
| percentage of participants | Placebo | BKZ Dosing Regimen 1 | BKZ Dosing Regimen 2 |
|---|---|---|---|
| Percentage of Participants Achieving Skin Pain Response at Week 16 | 10.9 (1.7 to 20.1) | 28.6 (19.5 to 37.8) | 31.8 (25.1 to 38.4) |
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. Treatment-emergent AEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week Safety Follow-Up \[SFU\] period).
| percentage of participants | Placebo | BKZ Dosing Regimen 1 | BKZ Dosing Regimen 2 | Placebo/BKZ Dosing Regimen 2 | BKZ Dosing Regimen 1/BKZ Dosing Regimen 1 | BKZ Dosing Regimen 2/BKZ Dosing Regimen 1 | BKZ Dosing Regimen 2/BKZ Dosing Regimen 2 |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study | 56.8 | 51.4 | 64.5 | 71.0 | 72.2 | 77.7 | 77.1 |
A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: Results in death; Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization; Results in persistent disability/incapacity; Is a congenital anomaly/birth defect; Important medical events. Treatment-emergent AEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period).
| percentage of participants | Placebo | BKZ Dosing Regimen 1 | BKZ Dosing Regimen 2 | Placebo/BKZ Dosing Regimen 2 | BKZ Dosing Regimen 1/BKZ Dosing Regimen 1 | BKZ Dosing Regimen 2/BKZ Dosing Regimen 1 | BKZ Dosing Regimen 2/BKZ Dosing Regimen 2 |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With Serious Treatment-emergent Adverse Events During the Study | 0 | 2.1 | 3.1 | 2.9 | 3.0 | 2.3 | 3.1 |
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. Treatment-emergent AEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period). TEAEs leading to discontinuation of the study are reported.
| percentage of participants | Placebo | BKZ Dosing Regimen 1 | BKZ Dosing Regimen 2 | Placebo/BKZ Dosing Regimen 2 | BKZ Dosing Regimen 1/BKZ Dosing Regimen 1 | BKZ Dosing Regimen 2/BKZ Dosing Regimen 1 | BKZ Dosing Regimen 2/BKZ Dosing Regimen 2 |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From the Study | 0 | 2.1 | 4.1 | 0 | 4.5 | 3.1 | 1.5 |
Collected over From Baseline (Day 1) until Safety Follow-Up (up to Week 71). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/74 (0%) | 0/74 (0%) | 18/74 (24.3%) |
| BKZ Dosing Regimen 1 | 0/142 (0%) | 3/142 (2.1%) | 40/142 (28.2%) |
| BKZ Dosing Regimen 2 | 0/290 (0%) | 9/290 (3.1%) | 101/290 (34.8%) |
| Placebo/BKZ Dosing Regimen 2 | 0/69 (0%) | 2/69 (2.9%) | 26/69 (37.7%) |
| BKZ Dosing Regimen 1/BKZ Dosing Regimen 1 | 0/133 (0%) | 4/133 (3%) | 49/133 (36.8%) |
| BKZ Dosing Regimen 2/BKZ Dosing Regimen 1 | 0/130 (0%) | 3/130 (2.3%) | 57/130 (43.8%) |
| BKZ Dosing Regimen 2/BKZ Dosing Regimen 2 | 0/131 (0%) | 4/131 (3.1%) | 64/131 (48.9%) |
| Event | Placebo | BKZ Dosing Regimen 1 | BKZ Dosing Regimen 2 | Placebo/BKZ Dosing Regimen 2 | BKZ Dosing Regimen 1/BKZ Dosing Regimen 1 | BKZ Dosing Regimen 2/BKZ Dosing Regimen 1 | BKZ Dosing Regimen 2/BKZ Dosing Regimen 2 |
|---|---|---|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 0/74 | 0/142 | 0/290 | 1/69 | 0/133 | 0/130 | 0/131 |
| AppendicitisInfections and infestations | 0/74 | 0/142 | 0/290 | 1/69 | 0/133 | 0/130 | 0/131 |
| HidradenitisSkin and subcutaneous tissue disorders | 0/74 | 0/142 | 2/290 | 0/69 | 1/133 | 1/130 | 0/131 |
| GastroenteritisInfections and infestations | 0/74 | 0/142 | 0/290 | 0/69 | 0/133 | 1/130 | 0/131 |
| DepressionPsychiatric disorders | 0/74 | 0/142 | 0/290 | 0/69 | 0/133 | 1/130 | 0/131 |
| Anal fissureGastrointestinal disorders | 0/74 | 0/142 | 0/290 | 0/69 | 0/133 | 0/130 | 1/131 |
| Anal fistulaGastrointestinal disorders | 0/74 | 0/142 | 0/290 | 0/69 | 0/133 | 0/130 | 1/131 |
| BartholinitisInfections and infestations | 0/74 | 0/142 | 0/290 | 0/69 | 0/133 | 0/130 | 1/131 |
| Rash pustularInfections and infestations | 0/74 | 0/142 | 0/290 | 0/69 | 0/133 | 0/130 | 1/131 |
| LymphoedemaVascular disorders | 0/74 | 0/142 | 0/290 | 0/69 | 0/133 | 0/130 | 1/131 |
| Event | Placebo | BKZ Dosing Regimen 1 | BKZ Dosing Regimen 2 | Placebo/BKZ Dosing Regimen 2 | BKZ Dosing Regimen 1/BKZ Dosing Regimen 1 | BKZ Dosing Regimen 2/BKZ Dosing Regimen 1 | BKZ Dosing Regimen 2/BKZ Dosing Regimen 2 |
|---|---|---|---|---|---|---|---|
| HidradenitisSkin and subcutaneous tissue disorders | 5/74 | 13/142 | 23/290 | 7/69 | 16/133 | 24/130 | 15/131 |
| Oral candidiasisInfections and infestations | 0/74 | 5/142 | 24/290 | 3/69 | 11/133 | 16/130 | 14/131 |
| HeadacheNervous system disorders | 7/74 | 7/142 | 18/290 | 3/69 | 7/133 | 4/130 | 7/131 |
| NasopharyngitisInfections and infestations | 0/74 | 3/142 | 11/290 | 2/69 | 6/133 | 8/130 | 11/131 |
| DiarrhoeaGastrointestinal disorders | 6/74 | 5/142 | 18/290 | 2/69 | 6/133 | 4/130 | 3/131 |
| FolliculitisInfections and infestations | 0/74 | 5/142 | 8/290 | 2/69 | 5/133 | 6/130 | 9/131 |
| Corona virus infectionInfections and infestations | 0/74 | 3/142 | 11/290 | 4/69 | 2/133 | 7/130 | 8/131 |
| Upper respiratory tract infectionInfections and infestations | 1/74 | 0/142 | 5/290 | 4/69 | 7/133 | 5/130 | 3/131 |
| EczemaSkin and subcutaneous tissue disorders | 1/74 | 1/142 | 9/290 | 4/69 | 5/133 | 5/130 | 3/131 |
| Vulvovaginal candidiasisInfections and infestations | 0/74 | 8/142 | 1/290 | 1/69 | 2/133 | 3/130 | 3/131 |
Baseline Characteristics refer to the RS which consisted of all study participants randomized into the study.
| Age, Categorical(Participants) | Placebo | BKZ Dosing Regimen 1 | BKZ Dosing Regimen 2 | Total |
|---|---|---|---|---|
| <=18 years | 0 | 7 | 10 | 17 |
| Between 18 and 65 years | 70 | 135 | 277 | 482 |
| >=65 years | 4 | 2 | 4 | 10 |
| Age, Continuous(Years) | Placebo | BKZ Dosing Regimen 1 | BKZ Dosing Regimen 2 | Total |
|---|---|---|---|---|
| Mean | 38.1 ± 13.2 | 35.2 ± 11.9 | 36.9 ± 12.3 | 36.6 ± 12.4 |
| Sex: Female, Male(Participants) | Placebo | BKZ Dosing Regimen 1 | BKZ Dosing Regimen 2 | Total |
|---|---|---|---|---|
| Female | 31 | 77 | 150 | 258 |
| Male | 43 | 67 | 141 | 251 |
| Race/Ethnicity, Customized(Participants) | Placebo | BKZ Dosing Regimen 1 | BKZ Dosing Regimen 2 | Total |
|---|---|---|---|---|
| American Indian or Alaskan Native | 0 | 0 | 1 | 1 |
| Asian | 5 | 7 | 22 | 34 |
| Black | 5 | 13 | 22 | 40 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| White | 64 | 119 | 232 | 415 |
| Other/mixed | 0 | 4 | 12 | 16 |
| Missing | 0 | 0 | 2 | 2 |
| Race/Ethnicity, Customized(Participants) | Placebo | BKZ Dosing Regimen 1 | BKZ Dosing Regimen 2 | Total |
|---|---|---|---|---|
| Hispanic or Latino | 5 | 10 | 15 | 30 |
| Not Hispanic or Latino | 69 | 134 | 274 | 477 |
| Missing | 0 | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Data sharing details ↗ · www.vivli.org
Ran from Mar 2020 to primary completion in Nov 2021, 20 months.
Results were first posted in Dec 2024, 3 years after primary completion. A results delay was requested in Nov 2022.
Of 26 phase 3 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 38. This study's 20 months is below that.
How these figures are worked out, and which studies are left out of them.
Aleshin MA, Tran T, Pansar I, Shang A, Friesen D, Kimball AB. Residual Burden in Adalimumab-Treated Patients with Hidradenitis Suppurativa: An Observational Co…PubMed 42525209 ↗; 1 more
Chovatiya R, Alavi A, Miyagawa T, Turchin I, Tzellos T, van der Zee HH, Crater C, Lukowski B, Tilt N, Zouboulis CC. Bimekizumab 2-year efficacy by hidradenitis…PubMed 42482599 ↗
Aleshin MA, Tran T, Pansar I, Shang A, Friesen D, Kimball AB. Residual Burden in Adalimumab-Treated Patients with Hidradenitis Suppurativa: An Observational Co…PubMed 42525209 ↗
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bimekizumab